Market Performance of NRX Pharmaceuticals, Inc. (NRXP)
NRXP closed the 24‑hour trading period ending at 09:56 AM Central Europe on Wednesday 21 March 2026 with an increase of 1.15 %. The share price stood at USD 2.62 on major exchanges.
| Item | Value |
|---|---|
| Shares outstanding | 43.3 million |
| Market capitalization | USD 112.5 million |
| 24‑hour trading volume | USD 2.9 million |
| Percentage change since last month‑end | –20.06 % |
| 200‑day simple moving average | USD 2.96 |
| 52‑week high | USD 5.06 (6 Feb 2026) |
| 52‑week low | USD 1.62 (9 Mar 2026) |
Peer Comparison (24‑hour performance)
| Stock | Ticker | % change | Current price | Market cap | Notable events |
|---|---|---|---|---|---|
| Ellington Credit | EARN | +1.73 % | USD 3.56 | USD 132.1 M | – |
| Comstock | LODE | –2.23 % | USD 1.74 | USD 133.6 M | – |
| Atrium Therapeutics | RNA | –0.78 % | USD 7.98 | USD 131.2 M | Granted stock options and RSUs to new non‑executive employee; raised USD 50 M in private placement; ongoing clinical programmes and collaboration with Bristol Myers Squibb |
| Legacy Education | LGCY | –0.10 % | USD 10.32 | USD 131.8 M | – |
| Maxcyte | MXCT | 0.00 % | USD 1.43 | USD 134.2 M | – |
Company Overview
NRX Pharmaceuticals, Inc. (NRXP) is a clinical‑stage pharmaceutical company headquartered in Wilmington, United States. The company focuses on the research and development of investigational medicines and vaccines targeting COVID‑19, respiratory diseases, suicidal depression, and PTSD. NRXP’s public listing was completed in November 2017, and the company trades on the Nasdaq stock exchange. Further information is available on the company’s website, www.nrxpharma.com .
